Cure My Disease

Don't miss your cure!

 Log in / Sign up

New stem cell combo could boost survival in blood cancer patients

NCT ID NCT07588360

Recruiting now Disease control Sponsor: Fujian Medical University Union Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new way to do stem cell transplants for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). It combines stem cells from a half-matched donor (haploidentical) with cord blood, given at different times. The goal is to help the body accept the new cells faster, lower the chance of the cancer coming back, and improve long-term survival. About 180 people aged 14 to 60 will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOID LEUKEMIA) MDS (MYELODYSPLASTIC SYNDROME)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese PLA General Hospital

    NOT_YET_RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fujian Medical University Union Hospital

    RECRUITING

    Fuzhou, Fujian, 350001, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Guangdong Provincial People's Hospital

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sichuan Provincial People's Hospital

    NOT_YET_RECRUITING

    Chengdu, Sichuan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.